The goal of this clinical trial is to analyse efficacy and safety of ixekizumab in participants with refractory guttate psoriasis. The main question it aims to answer is:
What percentage of participants achieved more than 90% reduction from baseline in Psoriasis Area Index （PASI 90） after 12 weeks of ixekizumab treatment? Participants will receive a 12-week treatment of ixekizumab, with follow-up visits every 2 weeks during the treatment period. Keep a diary of their symptoms and Psoriasis Area Index.

Start Date01 May 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT06786936

/ Not yet recruitingNot ApplicableIIT

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease.
Glutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms.
The strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism.
Patients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.

Start Date28 Feb 2025

Sponsor / Collaborator

NHS Greater Glasgow & Clyde

[+2]

NCT05309616

/ RecruitingPhase 2IIT

Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Start Date20 Feb 2025

Sponsor / Collaborator

Yale University

100 Clinical Results associated with Ixekizumab

100 Translational Medicine associated with Ixekizumab

100 Patents (Medical) associated with Ixekizumab

1,097

Literatures (Medical) associated with Ixekizumab

01 Mar 2025·Journal of the European Academy of Dermatology and Venereology

Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden

Article

Author: Saarelainen, L. ; Katus, U. ; Lee, J. ; Johnsson, I. ; Polesie, S. ; Sveide, I. ; Aher, K. ; Hoti, F. ; Hermanrud, C. ; Wennerström, C. ; Tskhvarashvili, G. ; Nissinen, R. ; Passey, A. ; Mälkönen, T. ; Westerlund, A. ; Hassan, F.

AbstractBackgroundPlaque psoriasis (PsO) requires long‐term treatment for symptom control and remission; thus, a long‐term pharmacological intervention is necessary. Treatment persistence reflects long‐term therapeutic effectiveness and tolerance.ObjectivesThis study investigates drug persistence and compares treatment discontinuation rates across biologic agents and apremilast used by PsO patients in Finland and Sweden.MethodsThis retrospective register‐based cohort study included bio‐naïve patients (≥18 years) with moderate‐to‐severe PsO, who initiated treatment with abatacept, adalimumab, brodalumab, certolizumab pegol, etanercept, golimumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab or apremilast during 2008–2020 in Finland or Sweden. The main analysis evaluated persistence (based on duration of continuous treatment) and compared rates of treatment discontinuation using guselkumab as reference drug, during 2018–2020 in Finland. Treatment discontinuation was assessed by survival analysis of the time to first drug discontinuation, including switching to other study drugs. Due to limited sample size (n < 20), certain biologics (abatacept, brodalumab, certolizumab pegol, etanercept, golimumab, risankizumab and tildrakizumab) were excluded from the persistence analysis.ResultsIn Finland, 709 patients fulfilled the inclusion criteria during 2018–2020 for the main analysis. The highest persistence was observed for guselkumab and ustekinumab with 90 and 85% of treated patients, respectively, continuing treatment for ≥1 year. Comparable results were observed in the expanded cohort analysis (index starting in 2008; 2745 bio‐naïve patients in Finland and 10,970 in Sweden). Furthermore, patients treated with guselkumab in Finland showed lower treatment discontinuation rates compared to other study drugs.ConclusionGuselkumab and ustekinumab demonstrated high persistence as measured by continued treatment for at least 1 year. Furthermore, these treatments demonstrated lower rates of discontinuation compared to other study drugs included in the analysis. Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates.

01 Mar 2025·American Journal of Clinical Dermatology

The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Study

Article

Author: Zhang, Xilin ; Huang, Dawei ; Liu, Xiaoke ; Lu, Jiajing ; Shi, Yuling ; Yao, Lingling ; Jiang, Yuxiong ; Ma, Rui ; Xu, Shuang ; Wang, Yu ; Li, Ying ; Zhong, Xiaoyuan

BACKGROUNDFamily history (FH) of psoriasis has been implicated as a risk factor for developing psoriasis. However, whether FH also carries information on clinical presentation and treatment response to biological agents in patients with psoriasis remains unclear.OBJECTIVEThis prospective, multicenter observational study aimed to analyze the clinical presentation and efficacy differences between patients with psoriasis with and without a FH.PATIENTS AND METHODSThe SPEECH registry is an observational, multicenter, and prospective registry that has been collecting data on psoriasis treatment since November 2022. This study included adult patients diagnosed with moderate-to-severe plaque psoriasis initiating treatment with biologics, including guselkumab, secukinumab, ixekizumab, ustekinumab, and adalimumab. FH of psoriasis was identified through patient self-report in which a positive FH was defined as a first-degree relative having psoriasis. The primary outcome measures include 75% improvement in Psoriasis Area and Severity Index (PASI75) and the Physician's Global Assessment score of cleared/minimal (PGA 0/1) after 3 months of treatment. Logistic regression was employed to determine the adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the achievement of response in selected outcomes for patients with a FH compared with those without a FH.RESULTSThe study included a total of 859 patients, of whom 22.9% had a FH of psoriasis. Patients with psoriasis who had a FH experienced an earlier onset of the disease and more severe anxiety symptoms than those without a FH. After 3 months of treatment, patients with psoriasis with a FH exhibited a higher likelihood of achieving PASI75 (aOR 1.60 [95% CI 1.02, 2.51]) and PGA 0/1 (aOR 1.54 [95% CI 1.03, 2.31]). Notably, these differences persisted after 6 months of treatment, confirming the sustained effectiveness of biologic treatments in patients with a positive FH. Further mediation analysis uncovered a significant indirect effect of FH on the treatment response to biologics through age of onset (p = 0.028), and the proportion mediated was 20.5%.CONCLUSIONFH of psoriasis may affect the clinical course of patients and enhance their treatment response to biologics, highlighting the importance of FH assessment in optimizing treatment outcome and guiding clinical decision of biologic selection. Future studies on biologic treatment responses in psoriasis should consider family history as a significant confounding factor.CHINESE CLINICAL TRIAL REGISTRYChiCTR2000036186.

01 Mar 2025·JCR: Journal of Clinical Rheumatology

Systematic Review and Meta-analysis

Article

Author: Mera, Antonio ; Carmona, Julia ; Maneiro, José Ramón ; Pérez-Pampín, Eva

BackgroundWe aimed to estimate the risk of malignancy associated with ixekizumab in randomized controlled trials (RCTs) and long-term extension studies (LTEs) in patients with rheumatological indications.MethodsA systematic review of the literature up to June 2024 was performed to analyze the risk of malignancy associated with ixekizumab use in patients with psoriatic arthritis and axial spondyloarthritis. The primary endpoint was overall malignancy risk in RCTs and LTEs. Meta-analyses of RCTs were performed when at least 3 studies had comparable outcome measures using Peto odds ratios. For LTEs, meta-analyses were performed using random-effects computing incidence rates (IRs) per 100 patient-years.ResultsTwelve articles, 4 LTEs and 8 pooled analyses, were included. Meta-analyses of RCTs for malignancy risk at week 24 showed a Peto odds ratio of 0.45 (0.11–1.86), with an I2 of 43.0%. When stratified according to the comparator, heterogeneity decreased. Malignancy risk comparing ixekizumab with placebo was 1.43 (0.18–11.53), with an I2 of 39.6%. Malignancy risk comparing ixekizumab with adalimumab was 0.11 (0.01–0.77), with an I2 of 0%. At week 52, the IR of all malignancies with ixekizumab was 0.31 (0.07–0.72), with an I2 of 18.9%. At 156 weeks, the IR of all malignancies with ixekizumab was 0.58 (0.29–0.96), with an I2 of 0%.ConclusionIxekizumab appears to confer a low malignancy risk in patients treated for rheumatological indications. Patients with psoriatic arthritis and axial spondyloarthritis appeared to be at similar risk, except for those with nonmelanoma skin cancer.

News (Medical) associated with Ixekizumab

12 Mar 2025

·www.prnewswire.com

Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As competition intensifies, these biosimilars are reshaping treatment choices and driving a shift in the market landscape. LAS VEGAS, March 12, 2025 /PRNewswire/ -- Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It is more prevalent in Europe and North America than in Asia and South America. In patients with psoriasis, the prevalence of psoriatic arthritis can range from 6% to 34% in Western populations. Despite its impact, many individuals with psoriatic arthritis remain undiagnosed or receive inadequate treatment, highlighting the need for increased awareness and access to specialized care. As per DelveInsight analysis, among the 7MM, the United States accounted for the highest number of prevalent cases of psoriatic arthritis in 2023, and these cases are expected to increase by the end of 2034 due to several key factors such as an increase in awareness and diagnosis, as well as the rapid prevalence of PsA. Psoriatic arthritis, occurring in approximately 20% of individuals with psoriasis, is a chronic inflammatory arthritis intricately linked to psoriatic arthritis. This aggressive condition is characterized by potential significant morbidity and compromised quality of life. Treatment approaches for psoriatic arthritis encompass a variety of strategies aimed at managing symptoms, slowing disease progression, and improving the overall quality of life. These approaches typically involve a combination of pharmacological therapies, lifestyle modifications, and, in severe cases, surgical interventions. Psoriatic arthritis treatment is highly individualized based on disease severity, response to therapy, and patient preferences, with multidisciplinary care from rheumatologists, dermatologists, and physical therapists playing a key role. Pharmacological treatment for psoriatic arthritis primarily targets inflammation and pain relief. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, are often the first line of defense, helping to reduce pain and inflammation. Disease-modifying antirheumatic drugs (DMARDs) like methotrexate, sulfasalazine, and leflunomide are commonly prescribed to prevent joint damage and suppress the inflammatory process. For individuals with mild-to-moderate psoriatic arthritis, oral small molecules (OSMs) like OTEZLA (apremilast) offer a convenient, non-injectable option by modulating inflammatory pathways. Biologic agents have revolutionized the treatment landscape for psoriatic arthritis. These medications specifically inhibit key molecules in the inflammatory cascade. TNF inhibitors like HUMIRA (adalimumab), ENBREL (etanercept), and REMICADE (infliximab) are frontline biologics that target tumor necrosis factor, a crucial driver of inflammation. Patients who do not respond to TNF inhibitors may benefit from IL-17 inhibitors like COSENTYX (secukinumab) and TALTZ (ixekizumab) or IL-12/23 inhibitors such as STELARA (ustekinumab). Learn more about the FDA-approved psoriatic arthritis drugs @ Drugs for Psoriatic Arthritis Treatment SKYRIZI (risankizumab), developed by AbbVie, is a humanized IgG1 monoclonal antibody that acts as an interleukin-23 (IL-23) antagonist. It can be used on its own or in conjunction with non-biologic DMARDs. In June 2022, the FDA approved SKYRIZI as the first and only targeted IL-23 inhibitor for adults with active psoriatic arthritis. Another biologic, TREMFYA (guselkumab by Janssen), was approved by the FDA in July 2020 as the first monoclonal antibody that selectively binds to the p19 subunit of IL-23, further expanding treatment options for psoriatic arthritis patients. BIMZELX (bimekizumab), developed by UCB Biopharma, is a humanized monoclonal antibody that targets IL-17A and IL-17F. It received European Commission approval in June 2023 for adults with active psoriatic arthritis and axial spondyloarthritis. On September 23, 2024, the FDA approved BIMZELX for treating adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis (nr-axSpA) with objective inflammation, and active ankylosing spondylitis. In Phase III studies, BIMZELX showed meaningful responses in patients with inadequate TNF inhibitor responses and those new to biologics, indicating its potential as an important treatment option for psoriatic arthritis. In cases where joint damage becomes severe and unresponsive to medical therapies, surgical interventions like joint replacement surgery may be necessary to restore function and alleviate pain. Lifestyle changes, such as regular exercise, joint protection techniques, and weight management, are also critical in managing psoriatic arthritis, as excess weight can worsen symptoms and increase disease severity. The treatment landscape for psoriatic arthritis continues to evolve, offering hope to patients with more targeted therapies and improved outcomes. As companies like UCB Biopharma, AbbVie, and Janssen advance their biologic portfolios, the future looks promising for psoriatic arthritis management. The competition in the biosimilar market is intensifying as companies introduce cost-effective alternatives to blockbuster biologics. In December 2024, Celltrion announced FDA approval for STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis. Simultaneously, Biocon Biologics Ltd. is strengthening its position with positive Phase III results for YESINTEK, its biosimilar to ustekinumab, in adult patients with moderate to severe chronic plaque psoriasis. The pivotal randomized, double-blind, parallel-group study demonstrated comparable efficacy and safety to the reference biologic, STELARA, and the findings are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. With the approval of STEQEYMA and the promising clinical outcomes for YESINTEK, these biosimilars are poised to challenge STELARA by offering cost-effective alternatives in key immunology indications. As pricing pressures and healthcare sustainability concerns drive the demand for biosimilars, these developments mark a significant shift in the treatment landscape, providing greater accessibility and affordability for patients while increasing competition in the immunology market. To know more about psoriatic arthritis treatment options, visit @ New Treatment for Psoriatic Arthritis The psoriatic arthritis market is buzzing with numerous companies advancing treatments to cater to the growing patient base. Several therapies are expected to enter the market during the forecast period, providing new hope for patients. Some of these potential therapies include ACELYRIN Inc.'s Izokibep, Novartis Pharmaceuticals' Secukinumab, UCB Biopharma SRL's Bimekizumab, and Bristol-Myers Squibb's Deucravacitinib. Additionally, AbbVie's Upadacitinib and Risankizumab, as well as Eli Lilly and Company's Ixekizumab, are also part of the promising pipeline. Other noteworthy therapies include Sun Pharma's ILUMYA/ILUMETRI, Bristol-Myers Squibb's SOTYKTU, and Affibody's Izokibep in collaboration with Acelyrin and Inmagene. With these advancements, the psoriatic arthritis treatment landscape is set for a major shift, offering patients more tailored and effective options. The companies involved in developing biosimilars include Alvotech, Teva, Biocon Biologics, Celltrion, Fresenius Kabi, and others. Discover which therapies are expected to grab major psoriatic arthritis market share @ Psoriatic Arthritis Market Report ILUMYA/ILUMETRI by Sun Pharma is an interleukin-23 (IL-23) inhibitor classified as a humanized, anti-IL-23p19 monoclonal antibody. It works by blocking inflammatory proteins (cytokines and chemokines) in the body. By inhibiting the effects of IL-23, ILUMYA helps control the release of other inflammatory proteins, including IL-17 and TNF-α. This mechanism reduces inflammation, decreases the number of inflammatory cells in psoriatic lesions, helps prevent plaque formation, and resolves tissue damage. The drug is currently undergoing evaluation in Phase III clinical development, actively recruiting subjects with active psoriatic arthritis who have prior exposure to anti-TNF agents, as well as those who are anti-TNF naïve. SOTYKTU, developed by Bristol-Myers Squibb, is the first and only novel oral selective tyrosine kinase 2 (TYK2) inhibitor being studied across multiple immune-mediated diseases. Deucravacitinib binds to the regulatory domain of the TYK2 enzyme, inhibiting its activation. This selective inhibition reduces the release of proinflammatory cytokines and chemokines, helping to control the inflammation associated with psoriatic arthritis and alleviating its signs and symptoms. Currently, the drug is being investigated for the treatment of psoriatic arthritis in a Phase III clinical trial. Izokibep, developed by Affibody in partnership with Acelyrin and Inmagene, is a unique antibody mimetic and a novel bispecific agent that potentially targets both subunits of the IL-17A homo-dimer and serum albumin. Affibody has entered into a partnership agreement with Acelyrin for the development and commercialization of izokibep and has completed a Phase II trial. As part of this agreement, Acelyrin obtained worldwide rights to izokibep, excluding selected Asian countries, where rights have been granted to Inmagene Biopharmaceuticals. In March 2024, Acelyrin announced the release of positive top-line results from the Phase IIb/III trial, indicating that izokibep was well-tolerated with a favorable safety profile. This drug is currently in Phase III clinical trial. Discover more about drugs for psoriatic arthritis in development @ Psoriatic Arthritis Clinical Trials The anticipated launch of these emerging therapies for psoriatic arthritis is poised to transform the market landscape in the coming years. As these cutting-edge treatments continue to mature and gain regulatory approval, they are expected to reshape the psoriatic arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the psoriatic arthritis market size was USD 9 billion in 2021 and is expected to grow significantly in the coming years. This growth can be attributed to the introduction of upcoming therapies and the rising prevalence of the condition. The anticipated launch of these therapies is also expected to attract new entrants to the psoriatic arthritis market, resulting in increased competition and innovation. DelveInsight's latest published market report titled " Psoriatic Arthritis Market Insight, Epidemiology, and Market Forecast – 2034" will help you discover which market leader is set to capture the largest market share. The report provides comprehensive insights into country-specific treatment guidelines, patient pool analysis, and epidemiology forecasts to help understand key opportunities and assess the market's underlying potential. The psoriatic arthritis market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of Psoriatic Arthritis Total Diagnosed Prevalent Cases of Psoriatic Arthritis Gender-specific Diagnosed Prevalent Cases of Psoriatic Arthritis Severity-specific Diagnosed Prevalent Cases of Psoriatic Arthritis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Psoriatic Arthritis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this psoriatic arthritis market report to assess the epidemiology forecasts, understand patient journeys, gain insights into KOLs' opinions about upcoming treatment paradigms, and identify the factors contributing to changes in the psoriatic arthritis market. Additionally, stay informed about the mitigating factors that can enhance your market position in the psoriatic arthritis therapeutic space. Related Reports Psoriatic Arthritis Pipeline Psoriatic Arthritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Affibody, Kymera, Selection Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, ACELYRIN Inc., among others. Psoriatic Arthritis Epidemiology Forecast Psoriatic Arthritis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Psoriatic Arthritis epidemiology trends. Ankylosing Spondylitis Market Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ankylosing Spondylitis companies, including UCB, AbbVie, Pfizer, Astella, Amgen, Janssen Biotech, Pozen, Novartis, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, among others. Psoriasis Market Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Psoriasis companies, including Amgen, Janssen, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalClinical ResultPhase 2

28 Feb 2025

·www.drugs.com

Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis

FRIDAY, Feb. 28, 2025 -- For patients with moderate-to-severe plaque psoriasis , ixekizumab is effective and safe, with induction therapy enhancing initial response, according to a study published online Jan. 29 in the Journal of Clinical Medicine . Ricardo Ruiz-Villaverde, M.D., Ph.D., from Hospital Universitario San Cecilio in Granada, Spain, and colleagues conducted a multicenter, observational study involving 183 patients with moderate-to-severe plaque psoriasis to examine the real-world effectiveness, safety, and drug survival of ixekizumab with and without an induction phase. Patients were divided into an induction group (160 mg at baseline, followed by 80 mg every two weeks through 12 weeks, then every four weeks) and a noninduction group (80 mg every four weeks from initiation). Baseline Psoriasis Activity Skin Index (PASI) and Physician Global Assessment scores were higher in the induction group, indicative of greater disease severity. The researchers observed significant clinical improvements with both regimens, with faster initial responses in the induction group. Lower drug survival was seen in the induction group, possibly due to higher baseline disease burden and severity. Comorbidities were prevalent, especially in the induction group, and included metabolic syndrome, cardiovascular risks, and psychiatric conditions. "While induction therapy appears to enhance initial PASI responses, meaningful long-term improvements can also be achieved without induction, particularly in patients with lower baseline disease activity," the authors write. "These findings underscore ixekizumab's versatility and durability as a therapeutic option, even in treatment-experienced populations." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

14 Feb 2025

·www.fiercepharma.com

UCB's Bimzelx outpacing AbbVie's Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey

There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis (PsA) launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake.The FDA approved Bimzelx, an IL-17A/IL-17F inhibitor, for use in active PsA in September 2024, adding to the authorization that UCB secured in plaque psoriasis 11 months earlier. Last month, Spherix surveyed 74 rheumatologists to gauge how the PsA launch was going. The market intelligence company found half of the physicians had trialed Bimzelx in PsA.Spherix compared the level of activity favorably to other launches, noting that awareness levels were higher for Bimzelx than for Rinvoq and Skyrizi and Johnson & Johnson’s Tremfya at the same point in their respective PsA launches. The three Bimzelx rivals are blockbusters, although PsA only accounts for some of their sales.The good news for UCB continued with the finding that rheumatologists rated Bimzelx more favorably than its analogs in terms of perceived advancement, satisfaction and patient candidacy. Still, the positive early signs are yet to translate into above-average uptake of the drug. Spherix found adoption metrics such as prescriber base and average number of PsA patients initiated are currently on par with or trailing those of benchmarked analogs. AbbVie’s Rinvoq saw the highest use at the three-month post-launch mark in PsA.Even so, there are signs Bimzelx is affecting the PsA market. Attracted by the perceived efficacy of the drug’s unique dual mechanism, rheumatologists are trialing Bimzelx in patients who were previously on other systemic therapies. A significant portion of patients are switching from TNF inhibitors, Spherix said, but there is also a notable number of people moving over from Novartis’ Cosentyx and Eli Lilly’s Taltz.Cosentyx and Taltz only target IL-17A, unlike the dual-mechanism Bimzelx. One rheumatologist said UCB’s drug “should work better than Cosentyx” based on the dual mechanism, but it is too early to tell clinically. Overall, rheumatologists with clinical experience of all three drugs said Bimzelx has an edge in terms of efficacy and data.Spherix’s broader study of the PsA market, which analyzed responses from 109 U.S. rheumatologists in the fourth quarter of 2024, suggested the IL-17 class is gaining ground, as the mechanism surpassed TNF inhibitors as the most-favored mechanism for the first time. Cosentyx is the top IL-17 therapy, Spherix said, and that position helped Novartis grow (PDF) sales of the drug by 25% last year. An analyst asked Novartis about Bimzelx on an earnings call late last month, questioning whether UCB’s “recent formulary wins” and hidradenitis suppurativa approval were affecting Cosentyx. In response, Novartis CEO Vas Narasimhan, M.D., said, “We’ve had to give the appropriate level of adjustments on our rebates, but we've maintained [a] very good formulary position,” adding that the company is bullish on hidradenitis suppurativa.“We think our profile of having very good flare resolution, where we showed very compelling data on flare, on pain, I think on itch, ... really gives us a very compelling dataset. And, given the long history of safety with Cosentyx, we think a very competitive profile to hopefully maintain that 60%-plus [new-to-brand prescription] share that we have,” Narasimhan said.

Drug ApprovalPhase 1Biosimilar

100 Deals associated with Ixekizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10071	Ixekizumab	L04AC13	DB11569

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Axial Spondyloarthritis	China	Eli Lilly & Co.	26 Jul 2022
Ankylosing Spondylitis	Canada	Eli Lilly & Co.	11 Aug 2016
Non-radiographic axial spondyloarthritis	Canada	Eli Lilly & Co.	11 Aug 2016
Spondylarthritis	Canada	Eli Lilly & Co.	11 Aug 2016
Erythrodermic psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis vulgaris	Japan	Eli Lilly Japan KK	04 Jul 2016
Pustular psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Arthritis, Psoriatic	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Plaque psoriasis	United States	Eli Lilly & Co.	22 Mar 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ankylosing Spondylitis	Phase 3	Mexico	Eli Lilly & Co.	01 Jul 2014
Ankylosing Spondylitis	Phase 3	Spain	Eli Lilly & Co.	01 Jul 2014
Ankylosing Spondylitis	Phase 3	Germany	Eli Lilly & Co.	01 Jul 2014
Ankylosing Spondylitis	Phase 3	United Kingdom	Eli Lilly & Co.	01 Jul 2014
Ankylosing Spondylitis	Phase 3	Netherlands	Eli Lilly & Co.	01 Jul 2014
Ankylosing Spondylitis	Phase 3	Belgium	Eli Lilly & Co.	01 Jul 2014
Arthritis, Psoriatic	Discovery	Russia	Eli Lilly & Co.	01 Dec 2012
Arthritis, Psoriatic	Discovery	Mexico	Eli Lilly & Co.	01 Dec 2012
Arthritis, Psoriatic	Discovery	Ukraine	Eli Lilly & Co.	01 Dec 2012
Plaque psoriasis	Discovery	Japan	Eli Lilly & Co.	16 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03364309 (Phase 3 Trial, Pubmed \| Adv Ther)	Phase 3	Psoriasis	289	Ixekizumab	bupufmdojr(qvwaqdwacn) = AEs were comparable in patients who received continuous treatment and retreatment aqbxpdymyq (dydacolgmx )	Positive	13 Nov 2024
NCT02696785 (COAST-V, Pubmed) Manual	Phase 3	Axial Spondyloarthritis bDMARD-naïve \| r-axSpA	81	Ixekizumab 80 mg every 4 weeks	(wxhqghdqer) = kjkyfufcdw pbydrhjgom (asaayjqdaf ) View more	Positive	01 Jul 2024
NCT04527380 (COSPIRIT-JIA, EULAR 12024 \| EULAR 22024) Manual	Phase 3	Enthesitis-Related Arthritis \| Juvenile Idiopathic Arthritis	101	Ixekizumab (All IXE)	(nxyhzmeewo) = cclcyysvem zvhkwpyrlc (neiivvcwwu ) View more	Positive	12 Jun 2024
				Ixekizumab (Bio-Naive)	(nxyhzmeewo) = fihlfeneaj zvhkwpyrlc (neiivvcwwu ) View more
NCT02696785 (COAST-V, EULAR2024)	Phase 3	Axial Spondyloarthritis	341	Ixekizumab Q4W	hxahebywdr(tyqanxzunz) = apzwjpdvlh ufhfzmfzmd (yzokesyfgv ) View more	Positive	05 Jun 2024
				Ixekizumab Q2W	hxahebywdr(tyqanxzunz) = cwfkbjuhjt ufhfzmfzmd (yzokesyfgv ) View more
EULAR2024	Not Applicable	Axial Spondyloarthritis First line HLA-B27	-	Ixekizumab	kipjqrlyzk(fayarylqko) = qoufxotapk kgimzgpuwp (dxjliwkvbf ) View more	Positive	05 Jun 2024
				Secukinumab	kipjqrlyzk(fayarylqko) = pbzfelbpwr kgimzgpuwp (dxjliwkvbf ) View more
EULAR2024	Not Applicable	Arthritis, Psoriatic \| Axial Spondyloarthritis interleukin 17A (IL17A)	335	Ixekizumab	fbeerfouvs(adoocbmbpi) = lzqkvteqyi cltqbzcmhm (hvfpociauu, 64.0 - 74.3)	Positive	05 Jun 2024
NCT01597245 \| NCT02561806 \| NCT03573323 \| NCT01646177 (UNCOVER-2 \| IXORA-R \| UNCOVER-3 \| IXORA-S \| PSoHO, Pubmed \| Dermatol Ther (Heidelb))	Not Applicable	Plaque psoriasis anti-interleukin (IL)-17A	-	Ixekizumab	nlcdfaddyq(ivvuhsytlg) = pqkrqkigno wxgwfxsmdk (qjewufdfvk ) View more	Positive	23 Mar 2024
NCT04285229 (Pubmed) Manual	Phase 3	Spondylarthritis	147	Ixekizumab 80 mg every 4 weeks	(knxpbcswah) = slzbsddvgq mgxzrvkmpd (fqpsfdqxbo )	Positive	01 Jan 2024
				Placeboixekizumab	(knxpbcswah) = gxepsjwbsh mgxzrvkmpd (fqpsfdqxbo )
EADV2023	Not Applicable	Arthritis, Psoriatic	84	Ixekizumab	uyrbqgnhqs(wikxdjvyiz) = inzxphvwrg safiqcfkah (vrmwyeyipz )	Positive	11 Oct 2023
WCD2023	Phase 2	Varicose Ulcer	4	Ixekizumab	sobncxjlna(dxpzieulss) = csfrhdwtoa frivokiylk (jizuvafzdk )	Positive	04 Jul 2023
				Placebo	sobncxjlna(dxpzieulss) = nlyytboqzb frivokiylk (jizuvafzdk )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis